<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1005233627
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NGENLA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SOMATROGON
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        795.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufcaturing Belgium N. V. " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufcaturing Belgium N. V. 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01AC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ngenla contains the active substance somatrogon, a modified form of human growth hormone. Natural human growth hormone is needed for bones and muscles to grow. It also helps your fat and muscle tissues to develop in the right amounts. Ngenla is used to treat children and adolescents from 3&nbsp;years of age who do not have enough growth hormone and are not growing at the normal rate.</p><p>&nbsp;</p><p>The active substance in Ngenla is made by &#39;recombinant DNA technology&#39;. This means that it is grown in cells that have been modified in the laboratory so that they can produce it.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use </strong><strong>Ngenla</strong><strong> </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care are allergic to somatrogon (see Warnings and precautions) or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care have an active tumour (cancer). Tell your doctor if you or the child in your care have or have had an active tumour. Tumours must be inactive, and you or the child in your care must have finished your anti-tumour treatment before starting treatment with Ngenla.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care have stopped growing because of closure of the growth plates (closed epiphyses) meaning that you or the child in your care have been told by your doctor that your bones have stopped growing.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care are seriously ill (for example, complications following open heart surgery, abdominal surgery, acute respiratory failure, multiple accidental trauma or similar conditions). If you or the child in your care are about to have, or have had, a major operation, or go into hospital for any reason, tell your doctor and remind the other doctors you are seeing that you use growth hormone.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before using Ngenla:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care develop a serious allergic reaction, stop using Ngenla, talk to your doctor right away. Sometimes serious allergic reactions such as hypersensitivity, including anaphylaxis or angioedema (difficulties breathing or swallowing, or swelling of the face, lips, throat or tongue) have occurred. If you or the child in your care have any of the following symptoms of a serious allergic reaction:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your face, mouth, and tongue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives (nettle rash, lumps rising under the skin)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care have replacement therapy with corticosteroid medicines (glucocorticoids) you or the child in your care should consult your doctor regularly as you or the child in your care may need adjustment of your glucocorticoid dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor should check at intervals how well the thyroid gland is working in you or the child in your care and if necessary may prescribe treatment or adjust the dose of existing treatment as this may be needed for Ngenla to work properly.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care have Prader-Willi syndrome, you or the child should not be treated with Ngenla unless you or the child in your care has growth hormone deficiency.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor should monitor you or the child in your care for high blood sugar levels (hyperglycaemia) during treatment with Ngenla. If you or the child in your care are treated with insulin or other diabetes medicines, your doctor may need to adjust the insulin dose. If you or the child in your care have diabetes and associated severe/worsening eye disease you or the child in your care should not be treated with Ngenla.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care have ever had any kind of tumour (cancer).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care experience changes in vision, severe or frequent headaches, associated with feeling sick (nausea), vomiting, or experience lack of muscle control or coordination of voluntary movements, such as walking or picking up objects, difficulty with speech, eye movement or swallowing, especially at the start of treatment, tell your doctor immediately. These could be signs of a temporary increase in pressure within the brain (intracranial hypertension).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care are seriously ill (for example, complications following open heart surgery, abdominal surgery, acute respiratory failure, multiple accidental trauma or similar conditions). If you or the child in your care are about to have, or have had, a major operation, or go into hospital for any reason, tell your doctor and remind the other doctors you are seeing that you or the child in your care use growth hormone.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care develop a severe stomach ache during treatment with Ngenla as this could be a symptom of inflammation of the pancreas.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care notice a sideways curvature in your spine (scoliosis), you or the child in your care will need to be checked often by your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If during growing you or the child in your care develop a limp or hip or knee pain, you or the child in your care should consult your doctor right away. These could be symptoms of bone disorders in your hip as this may happen during periods of rapid growth.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care are taking or stop taking oral contraception or hormonal replacement therapy with oestrogen, your doctor may recommend the dose of Ngenla to be adjusted.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Ngenla</strong></p><p>Tell your doctor, pharmacist or nurse if you or the child in your care are using, have recently used or might use any other medicines.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care take replacement therapy with corticosteroid medicines (glucocorticoids), as these may reduce the effect of Ngenla on growth. You or the child in your care should consult your doctor regularly, as you or the child in your care may need adjustment of your glucocorticoid dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care are treated with insulin or other diabetes medicines, you should consult with your doctor as you or your doctor may need to adjust the dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care are receiving treatment with thyroid hormones, your doctor may need to adjust the dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care are receiving oestrogen taken orally, you should consult your doctor as you or the child may need to adjust your dose of Ngenla.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care are receiving ciclosporin (a medicine that weakens the immune system after transplantation), you should consult your doctor as your doctor may need to adjust the dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you or the child in your care are receiving medicines to control epilepsy (anticonvulsants), you should consult your doctor as your doctor may need to adjust the dose.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you or the child in your care are pregnant or breast-feeding, think you or the child in your care may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Ngenla has not been tested in pregnant women and it is not known if this medicine can harm your unborn baby. It is therefore preferable to avoid Ngenla during pregnancy. If you are able to get pregnant, you should not use Ngenla unless you are also using reliable contraception.</p><p>&nbsp;</p><p>It is not known whether somatrogon can pass into breast milk. Tell your doctor or the doctor of the child in your care, if you or the child in your care are breast‑feeding or plan to do so. Your doctor will then help you or the child in your care decide whether to stop breast-feeding, or whether to stop taking Ngenla, considering the benefit of breast-feeding to the baby and the benefit of Ngenla to you or the child in your care.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Ngenla does not affect the ability to drive and use machines.</p><p><strong>&nbsp;</strong></p><p><strong>Ngenla contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p><strong>&nbsp;</strong></p><p><strong>Ngenla contains metacresol</strong></p><p>Ngenla contains a preservative called metacresol. In very rare cases the presence of metacresol can cause inflammation (swelling) in muscles. If you or the child in your care experience muscle pain or pain at the injection site, inform your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine will only be prescribed by a doctor who has experience with growth hormone treatment and who has confirmed your diagnosis or that of the child in your care.</p><p>&nbsp;</p><p>Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>&nbsp;</p><p>The dose of Ngenla to be injected will be decided by your doctor.</p><p>&nbsp;</p><p><strong>How much to use</strong></p><p>Your doctor will work out your dose of Ngenla from your body weight in kilograms. The recommended dose is 0.66&nbsp;mg per kg body weight and is given once weekly. If you or the child in your care have been previously treated with daily growth hormone injections, your doctor will tell you to wait before taking the first dose of Ngenla until the day after your last daily injection and then continue with Ngenla once each week.</p><p>&nbsp;</p><p>Do not change your dose unless your doctor has told you to.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>How Ngenla is given</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ngenla is available as a pre-filled pen in 2 different sizes (Ngenla 24&nbsp;mg and Ngenla 60&nbsp;mg). Based on the recommended dose your doctor or the doctor of the child in your care will prescribe the most appropriate pen size (see section 6 &ldquo;Further information&rdquo;).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before you or the child in your care use the pen for the first time, your/their doctor or nurse will show you how to use it. Ngenla is given as an injection under the skin (subcutaneous injection) using a pre-filled pen. Do not inject it into a vein or muscle.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The best place to give Ngenla is in the abdomen (belly), thighs, buttocks or upper arms. Injections to the upper arms and buttocks should be given by the caregiver.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change the site of injection on your body, or on the body of the child in your care, each time a dose is administered.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If more than one injection is required to deliver a complete dose, each should be administered at a different injection site.</p><p>&nbsp;</p><p>Detailed instructions for use of the pre-filled pen are at the end of this leaflet.</p><p><strong>&nbsp;</strong></p><p><strong>When to use Ngenla</strong></p><p>You or the child in your care should use this medicine once a week on the same day each week.</p><p>&nbsp;</p><p>You or the child in your care should record which day of the week you use Ngenla to help you or the child in your care remember to inject this medicine once a week.</p><p>&nbsp;</p><p>If necessary you or the child in your care can change the day of your/their weekly injection as long as it has been at least 3&nbsp;days since you or the child in your care had your/their last injection. After selecting a new dosing day, continue giving yourself or the child in your care the injection on that day each week.</p><p>&nbsp;</p><p><strong>If you use more Ngenla </strong><strong>than you should</strong></p><p>If you or the child in your care have injected more Ngenla than you should have been given, contact your doctor straight away as your/their blood sugar levels may need to be checked.</p><p>&nbsp;</p><p><strong>If you forget to use Ngenla</strong></p><p>If you or the child in your care forgot to inject a dose and:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is 3&nbsp;days or less since you or the child in your care should have used Ngenla, use it as soon as you remember. Then inject your/their next dose on your/their usual injection day.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is more than 3&nbsp;days since you or the child in your care should have used Ngenla, skip the missed dose. Then inject your/their next dose as usual on your/their next scheduled day. A regular dosing day should be maintained.</p><p>&nbsp;</p><p>Do not use a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop using Ngenla</strong></p><p>Do not stop using this medicine without talking to your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Very common: may affect more than 1 in 10 people</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding, inflammation, itching, pain, redness, soreness, stinging, tenderness, or warmth at the injection site (injection site reactions)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever (pyrexia)</p><p>&nbsp;</p><p><strong>Common: may affect up to 1 in 10 people</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in the number of red blood cells in the blood (anaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in the number of eosinophils in the blood (eosinophilia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in the blood level of thyroid hormone (hypothyroidism)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic inflammation of the conjunctiva, the clear layer over the outside of the eye (allergic conjunctivitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain (arthralgia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in arms or legs</p><p>&nbsp;</p><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The adrenal glands do not make enough steroid hormones (adrenal insufficiency)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&nbsp;</p><p><strong>Other possible side effects not seen with Ngenla but which have been reported in other growth hormone medicines treatment may include the following: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tissue growth (non cancerous or cancer)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Type 2 diabetes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased intracranial pressure (which causes symptoms such as strong headache, visual disturbances or vomiting)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness or tingling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint or muscle pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast enlargement in boys and men</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash, reddening and itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water retention (which shows as puffy fingers or swollen ankles)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Facial swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pancreatitis (which causes symptoms of stomach pain, nausea, vomiting or diarrhoea)</p><p><em>&nbsp;</em></p><p>In very rare cases the presence of metacresol can cause inflammation (swelling) in muscles. If you or the child in your care experience muscle pain or pain at the injection site, inform your doctor.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you or the child in your care get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:456px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other </strong><strong>GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the pen label and on the carton after &lsquo;EXP.&rsquo; The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>The pre-filled pen should not be used more than 28&nbsp;days after first use.</p><p>&nbsp;</p><p><u>Before first use of </u><u>Ngenla</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator (2&nbsp;&deg;C ‑ 8&nbsp;&deg;C). Do not freeze.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep Ngenla in the outer carton in order to protect from light.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove Ngenla from the refrigerator prior to use. Ngenla may be held at room temperature (up to 32&nbsp;&deg;C) for up to 4&nbsp;hours.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice that the solution is cloudy or dark yellow. Do not use the medicine if it has flakes or particles.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not shake the pen. Shaking can damage the medicine.</p><p>&nbsp;</p><p><u>After first use of </u><u>Ngenla</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use within 28&nbsp;days after first use. Store in a refrigerator (2&nbsp;&deg;C ‑ 8&nbsp;&deg;C). Do not freeze.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep Ngenla with the pen cap on in order to protect from light.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store the pre-filled pen with a needle attached.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discard the pen after last dose, even if it contains unused medicine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ngenla may be held at room temperature (up to 32&nbsp;&deg;C) for up to 4&nbsp;hours with each injection for a maximum of 5&nbsp;times. Return Ngenla to the refrigerator again after each use.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not leave at room temperature for more than 4&nbsp;hours with each use.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not put the pen anywhere that the temperature goes above 32&nbsp;&deg;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If it has been more than 28&nbsp;days after first use of your pen, get rid of it even if it contains unused medicine. If your pen or the pen of the child in your care has been exposed to temperatures higher than 32&nbsp;&deg;C, or has been removed from the refrigerator for more than 4&nbsp;hours with each use or if it has been used a total of 5&nbsp;times, get rid of it even if it contains unused medicine.</p><p>&nbsp;</p><p>To help you remember when to dispose of your pen you can write the date of first use on the pen label.</p><p>&nbsp;</p><p>A small amount of medicine may remain in the pen after all doses have been correctly given. Do not try to use any remaining medicine. After the last dose is given, the pen must be properly thrown away.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is somatrogon.</p><p>&nbsp;</p><p><u>Ngenla</u><u> </u><u>24&nbsp;mg solution for injection in pre-filled pen</u></p><p>One mL of solution contains 20&nbsp;mg of somatrogon.</p><p>Each pre-filled pen contains 24&nbsp;mg somatrogon in 1.2&nbsp;mL of solution. Each pre-filled pen delivers doses from 0.2&nbsp;mg to 12&nbsp;mg in a single injection in 0.2&nbsp;mg increments.</p><p>&nbsp;</p><p><u>Ngenla 60&nbsp;mg solution for injection in pre-filled pen</u></p><p>One mL of solution contains 50&nbsp;mg of somatrogon.</p><p>Each pre-filled pen contains 60&nbsp;mg somatrogon in 1.2&nbsp;mL solution. Each pre-filled pen delivers doses from 0.5&nbsp;mg to 30&nbsp;mg in a single injection in 0.5&nbsp;mg increments.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: trisodium citrate dihydrate, citric acid monohydrate, L-Histidine, sodium chloride (see section 2 &ldquo;Ngenla contains sodium&rdquo;), poloxamer 188, m‑Cresol, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Ngenla is a clear and colourless to slightly light yellow solution for injection (injection) in a pre-filled pen. 
	
	Ngenla 24 mg solution for injection is available in a pack size containing 1 pre filled pen. The pen cap, dose button, and label on the pen are coloured lilac.
	
	Ngenla 60 mg solution for injection is available in a pack size containing 1 pre-filled pen. The pen cap, dose button, and label on the pen are coloured blue.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Europe MA EEIG</p><p>Boulevard de la Plaine 17</p><p>1050 Bruxelles</p><p>Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Pfizer Manufacturing Belgium NV</p><p>Puurs, Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي نجينلا على المادة الفعالة سوماتروجون، وهي شكل معدل لهرمون النمو البشري. وهرمون النمو البشري الطبيعي ضروري لنمو العظام والعضلات. وهو يساعد أيضًا على نمو أنسجتك الدهنية والعضلية بالمقدار المناسب. ويستخدم نجينلا لعلاج الأطفال والمراهقين من سن ٣ أعوام ممن ليس لديهم مستويات كافية من هرمون النمو ولا ينمون بالمعدل الطبيعي.</p><p>&nbsp;</p><p dir="RTL">تصنع المادة الفعالة في نجينلا باستخدام &quot;تقنية الحمض النووي (DNA) المأشوب&quot;. ويعني هذا أنها تنمو في خلايا خضعت للتعديل في المعمل بحيث تنتج هذه المادة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;<strong>موانع استعمال نجينلا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا أنت أو الطفل الذي ترعاه بحساسية تجاه سوماتروجون (انظر الاحتياطات عند استعمال نجينلا) أو تجاه أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت مصابًا أنت أو الطفل الذي ترعاه بورم نشط (سرطان). عليك إخبار طبيبك إذا كنت مصابًا أنت أو الطفل الذي ترعاه بورم نشط أو سبقت لكما الإصابة به. ويجب أن تكون الأورام التي تعاني منها أنت أو الطفل الذي ترعاه غير نشطة، وكذلك يجب إكمال العلاج المضاد للأورام قبل بدء العلاج بنجينلا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا توقفت أنت أو الطفل الذي ترعاه عن النمو بسبب انغلاق صفائح النمو (انغلاق المُشاش)، أي أن الطبيب قد أخبرك أن عظامك أنت أو الطفل الذي ترعاه قد توقفت عن النمو.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أنت أو الطفل الذي ترعاه من حالة مرضية خطيرة (على سبيل المثال، المضاعفات التالية لجراحة قلب مفتوح، أو جراحة بطن، أو فشل رئوي حاد، أو رضوح عرضية متعددة، أو حالات مشابهة). إذا كنت أنت أو الطفل الذي ترعاه على وشك الخضوع، أو قد خضعتما بالفعل، لعملية جراحية كبيرة أو كنتما على وشك الدخول إلى المستشفى لأي سبب كان، فأخبر طبيبك وذكِّر الأطباء الآخرين المشرفين على الحالة بأنكما تتلقيان هرمون النمو.</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال نجينلا</strong></p><p dir="RTL">&nbsp;تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل استخدام نجينلا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا أصبت أنت أو الطفل الذي ترعاه بتفاعل حساسية خطير، فأوقف استخدام نجينلا وتحدث إلى الطبيب فورًا. فقد حدثت في بعض الأحيان تفاعلات حساسية خطيرة مثل فرط الحساسية، بما في ذلك التأق أو الوذمة الوعائية (صعوبات في التنفس أو البلع، أو تورم الوجه أو الشفتين أو الحلق أو اللسان). إذا ظهرت عليك أنت أو الطفل الذي ترعاه أي من الأعراض التالية التي تدل على الإصابة بتفاعل حساسية خطير:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;مشكلات في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، والفم، واللسان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (الطفح الجلدي القراصي، كتل بارزة تحت الجلد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تتلقى أنت أو الطفل الذي ترعاه علاجًا بديلًا بأدوية الستيرويدات القشرية (القشرانيات السكرية)، ينبغي لك أو للطفل الذي ترعاه استشارة الطبيب بشكل منتظم لأنكما قد تحتاجان إلى تعديل جرعة القشرانيات السكرية التي تتلقيانها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي للطبيب أن يتحقق على فترات من كفاءة عمل الغدة الدرقية لديك أو لدى الطفل الذي ترعاه، وإذا لزم الأمر، فقد يصف علاجًا أو يُعدل جرعة العلاج الحالي لأن ذلك قد يكون ضروريًا لكي يعمل نجينلا بشكل سليم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت أنت أو الطفل الذي ترعاه مصابين بمتلازمة برادر-ويلي، ينبغي ألا تخضعا للعلاج بنجينلا إلا في حالة الإصابة بنقص هرمون النمو.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي للطبيب مراقبتك أنت أو الطفل الذي ترعاه تحسبًا لارتفاع مستويات سكر الدم (فرط سكر الدم) في أثناء العلاج بنجينلا. وإذا كنت تتلقى أنت أو الطفل الذي ترعاه علاجًا بالإنسولين أو أدوية داء السكري الأخرى، فقد يحتاج الطبيب إلى تعديل جرعة الإنسولين. وإذا كنت مصابًا أنت أو الطفل الذي ترعاه بداء السكري وأمراض العين الشديدة/المتفاقمة المرتبطة به، ينبغي ألا تخضعا للعلاج بنجينلا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق وأن أصبت أنت أو الطفل الذي ترعاه بأي نوع من الأورام (السرطان).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت أنت أو الطفل الذي ترعاه بتغيرات في الرؤية، أو نوبات صداع متكررة أو شديدة يصاحبها شعور بالرغبة في التقيؤ (الغثيان)، أو القيء، أو كنت تعاني من ضعف التحكم في العضلات أو تنسيق الحركات الإرادية، كالمشي أو التقاط الأشياء، أو صعوبة الكلام أو تحريك العين أو البلع، وخصوصًا في بداية العلاج، فأخبر الطبيب فورًا. فقد تكون هذه علامات على الارتفاع المؤقت في الضغط داخل الدماغ (ارتفاع ضغط الدم داخل القحف).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تعاني أنت أو الطفل الذي ترعاه من حالة مرضية خطيرة (على سبيل المثال، المضاعفات التالية لجراحة قلب مفتوح، أو جراحة بطن، أو فشل رئوي حاد، أو رضوح عرضية متعددة، أو حالات مشابهة). وإذا كنت أنت أو الطفل الذي ترعاه على وشك الخضوع، أو قد خضعتما بالفعل، لعملية جراحية كبيرة أو كنتما على وشك الدخول إلى المستشفى لأي سبب كان، فأخبر الطبيب وذكِّر الأطباء الآخرين المشرفين على حالتك بأنك تتلقى أنت أو الطفل الذي ترعاه هرمون النمو.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت أنت أو الطفل الذي ترعاه بألم شديد في المعدة في أثناء العلاج بنجينلا، حيث قد يكون ذلك من أعراض التهاب البنكرياس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت أنت أو الطفل الذي ترعاه وجود انحناء جانبي في العمود الفقري (الجنف)، فسيلزم أن تخضع أنت أو الطفل الذي ترعاه للفحص على يد الطبيب بصورة متكررة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا أصبت أنت أو الطفل الذي ترعاه بعرج أو ألم في الورك أو الركبة في أثناء النمو، ينبغي استشارة الطبيب فورًا. فقد تكون هذه أعراضًا لاضطرابات عظمية في الورك، حيث قد يحدث ذلك في أثناء فترات النمو السريع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ أنتِ أو الطفلة التي ترعينها تتلقيان حاليًا أو توقفتما عن تلقي وسائل منع حمل الفموية أو العلاج بالهرمونات البديلة بالإستروجين، فقد يوصي الطبيب بتعديل جرعة نجينلا.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا كنت أنت أو الطفل الذي ترعاه تستخدمان حاليًا أو استخدمتما مؤخرًا أو قد تستخدمان أي أدوية أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا تلقيت أنت أو الطفل الذي ترعاه علاجًا بديلًا بأدوية الستيرويدات القشرية (القشرانيات السكرية)، حيث قد تقلل هذه الأدوية من تأثير نجينلا على النمو. ينبغي لك أو للطفل الذي ترعاه استشارة الطبيب بشكل منتظم لأنكما قد تحتاجان إلى تعديل جرعة القشرانيات السكرية التي تتلقيانها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى أنت أو الطفل الذي ترعاه علاجًا بالإنسولين أو أدوية داء السكري الأخرى، ينبغي استشارة الطبيب حيث قد يتعين عليك أنت أو الطبيب تعديل جرعة الإنسولين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى أنت أو الطفل الذي ترعاه علاجًا بهرمونات الغدة الدرقية، فقد يتعين على الطبيب تعديل الجرعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ أنت أو الطفلة التي ترعينها تتلقيان الإستروجين فمويًا، ينبغي استشارة الطبيب، حيث قد تكوني أنتِ أو الطفلة بحاجة إلى تعديل جرعة نجينلا التي تتلقيانها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى أنت أو الطفل الذي ترعاه سيكلوسبورين (دواء يضعف الجهاز المناعي بعد عمليات الزرع)، ينبغي استشارة الطبيب لأنه قد يتعين عليه تعديل الجرعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى أنت أو الطفل الذي ترعاه أدوية للتحكم في الصرع (مضادات التشنجات)، ينبغي استشارة الطبيب لأنه قد يتعين عليه تعديل الجرعة.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;إذا كنتِ حاملًا أنتِ أو الطفلة التي ترعينها أو ترضعان رضاعة طبيعية، أو تعتقدين أنكِ قد تكونين حاملًا أنتِ أو الطفلة التي ترعينها، أو تخططان للإنجاب، فاستشيري الطبيب أو الصيدلي قبل تلقي هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">لم يتم اختبار نجينلا على السيدات الحوامل، وليس معروفًا ما إذا كان هذا الدواء يمكنه أن يسبب ضررًا لجنينكِ. وبالتالي يفضَّل تجنب تلقي نجينلا في أثناء الحمل. وإذا كنتِ قادرة على الإنجاب، ينبغي ألا تستخدمي نجينلا ما لم تكوني تستخدمين أيضًا وسيلة منع حمل موثوقة.</p><p>&nbsp;</p><p dir="RTL">من غير المعروف ما إذا كان سوماتروجون يمكنه المرور إلى لبن الثدي أم لا. ولهذا أخبري طبيبكِ أو طبيب الطفلة التي ترعينها إذا كنتما ترضعان رضاعة طبيعية أو تخططان لذلك. فعندها سيساعدكِ الطبيب أنتِ أو الطفلة التي ترعينها في اتخاذ القرار بشأن ما إذا كان ينبغي إيقاف الرضاعة الطبيعية أو إيقاف تلقي نجينلا، مع الأخذ في الاعتبار فوائد الرضاعة الطبيعية للرضيع وفوائد نجينلا لكما.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثير نجينلا على القيادة واستخدام الآلات</strong></p><p dir="RTL">لا يؤثر نجينلا على القدرة على القيادة واستخدام الآلات.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&zwnj;معلومات هامة حول بعض مكونات نجينلا</strong><br /><strong>يحتوي نجينلا على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ۱ مليمول من الصوديوم (٢٣ ملجم) لكل جرعة، أي أنه يُعد &quot;خاليًا من الصوديوم&quot; بشكل أساسي.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي نجينلا على ميتاكريزول</strong></p><p dir="RTL">يحتوي نجينلا على مادة حافظة تسمى ميتاكريزول. وفي بعض الحالات النادرة للغاية، يمكن أن يسبب وجود ميتاكريزول التهابًا (تورمًا) في العضلات. ولهذا، إذا أصبت أنت أو الطفل الذي ترعاه بألم في العضلات أو في موضع الحقن، فأخبر الطبيب.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لن يوصف هذا الدواء إلا من قِبل طبيب له خبرة في العلاج بهرمون النمو بعد أن يؤكد تشخيص حالتك أنت أو الطفل الذي ترعاه.</p><p>&nbsp;</p><p dir="RTL">احرص دائمًا على استخدام هذا الدواء تمامًا كما أخبرك طبيبك. راجع طبيبك أو الصيدلي أو الممرضة إذا كنت غير متأكد مما ينبغي لك فعله.</p><p>&nbsp;</p><p dir="RTL">&nbsp;سيحدد طبيبك جرعة نجينلا اللازم حقنها.</p><p>&nbsp;</p><p dir="RTL">&nbsp;<strong>مقدار الجرعة التي ينبغي استخدامها</strong></p><p dir="RTL">سيحسب طبيبك جرعة نجينلا التي ستتلقاها وفقًا لوزن جسمك بالكيلوجرام. والجرعة الموصى بها هي ٠,٦٦ ملجم لكل كلجم من وزن الجسم، وتُعطَى مرة واحدة أسبوعيًا. ولكن إذا كنت قد عولجت سابقًا أنت أو الطفل الذي ترعاه باستخدام حقن يومية من هرمون النمو، فسيخبرك الطبيب أن تنتظر حتى اليوم التالي لموعد تلقي آخر حقنة يومية قبل أن تتلقي أول جرعة من نجينلا، ثم تابع استخدام نجينلا مرة واحدة كل أسبوع.</p><p>&nbsp;</p><p dir="RTL">لا تغير مقدار الجرعة التي تتلقاها ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>طريقة استخدام نجينلا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوفر نجينلا في صورة قلم مسبق التعبئة بحجمين مختلفين (نجينلا ٢٤ ملجم ونجينلا ٦٠ ملجم). واستنادًا إلى الجرعة الموصى بها، سيصف طبيبك أو طبيب الطفل الذي ترعاه حجم القلم الأنسب (انظر القسم ٦ &quot;معلومات إضافية&quot;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل أن تستخدم أنت أو الطفل الذي ترعاه القلم لأول مرة، سيريك طبيبك/طبيبه أو الممرضة كيفية استخدامه. يُعطَى نجينلا عن طريق الحقن تحت الجلد باستخدام قلم مسبق التعبئة. فلا تحقنه في الأوردة أو العضلات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;يُعد أفضل مكان لإعطاء نجينلا هو منطقة البطن، أو الفخذين، أو الردفين، أو أعلى الذراعين. وينبغي أن تُجرى عمليات الحقن في أعلى الذراعين والردفين من قِبل القائم على الرعاية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غيّر موضع الحقن في جسمك أو جسم الطفل الذي ترعاه عند إعطاء كل جرعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الحاجة إلى تلقي أكثر من حقنة واحدة للحصول على الجرعة الكاملة، ينبغي إعطاء كل واحدة في موضع حقن مختلف.</p><p>&nbsp;</p><p dir="RTL">توجد تعليمات استخدام مفصلة حول القلم مسبق التعبئة في نهاية هذه النشرة.</p><p><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;<strong>متى ينبغي أن تستخدم نجينلا</strong></p><p dir="RTL">ينبغي أن تستخدم أنت أو الطفل الذي ترعاه هذا الدواء مرة واحدة أسبوعيًا في نفس اليوم من كل أسبوع.</p><p>&nbsp;</p><p dir="RTL">&nbsp;ينبغي أن تسجل أنت أو الطفل الذي ترعاه اليوم الأسبوعي المخصص لاستخدام نجينلا وذلك لمساعدتك أنت أو الطفل الذي ترعاه على تذكر حقن هذا الدواء مرة واحدة أسبوعيًا.</p><p>&nbsp;</p><p dir="RTL">إذا لزم الأمر، يمكنك أنت أو الطفل الذي ترعاه تغيير يوم تلقي حقنتك/حقنته الأسبوعية بشرط مرور ما لا يقل عن ٣ أيام على تلقيك أنت أو الطفل الذي ترعاه للحقنة الأخيرة. بعد اختيار يوم جديد لتلقي الجرعات، استمر في إعطاء الحقنة لنفسك أو للطفل الذي ترعاه في ذلك اليوم من كل أسبوع.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من نجينلا</strong></p><p dir="RTL">إذا تلقيت أنت أو الطفل الذي ترعاه نجينلا بكمية أكبر مما ينبغي، فاتصل بطبيبك فورًا حيث قد تحتاج أنت/الطفل الذي ترعاه إلى إجراء فحص لمستويات السكر في الدم.</p><p>&nbsp;</p><p dir="RTL">&nbsp;<strong>نسيان تناول جرعة نجينلا</strong></p><p dir="RTL">إذا نسيت أنت أو الطفل الذي ترعاه حقن إحدى الجرعات و:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت قد مرت ٣ أيام أو أقل على الوقت الذي كان ينبغي لك أنت أو الطفل الذي ترعاه استخدام نجينلا فيه، فاستخدمه بمجرد أن تتذكر. ثم احقن جرعتك/جرعته التالية في يوم الحقن المعتاد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت قد مرت فترة تزيد عن ٣ أيام على الوقت الذي كان ينبغي لك أنت أو الطفل الذي ترعاه استخدام نجينلا فيه، فتخط الجرعة الفائتة. ثم احقن جرعتك/جرعته التالية كالمعتاد في اليوم التالي المجدول. ينبغي الالتزام بتلقي الجرعات في اليوم المعتاد.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم جرعة مضاعفة لتعويض جرعة منسية.</p><p>&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول نجينلا</strong></p><p dir="RTL">لا توقف استخدام هذا الدواء دون التحدث إلى طبيبك.</p><p>&nbsp;</p><p dir="RTL">&nbsp;إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء أعراضًا جانبية، غير أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة جدًا: قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف، أو التهاب، أو حكة، أو ألم، أو احمرار، أو وجع، أو وخز، أو إيلام، أو دفء في موضع الحقن (تفاعلات موضع الحقن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (السخونة)</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم الحمراء في الدم (فقر الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في عدد اليوزينيات في الدم (كثرة اليوزينيات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في مستوى هرمونات الغدة الدرقية في الدم (قصور الغدة الدرقية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الملتحمة التحسسي، وهي الطبقة الشفافة التي تغطي الجزء الخارجي من العين (التهاب الملتحمة الأرجي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل (الألم المفصلي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الذراعين أو الساقين</p><p>&nbsp;</p><p dir="RTL">&nbsp;<strong>غير شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم إفراز الغدتين الكظريتين لكميات كافية&nbsp; من الهرمونات الستيرويدية (قصور الغدة الكظرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p>&nbsp;</p><p dir="RTL">&nbsp;<strong>الأعراض الجانبية المحتملة الأخرى التي لم تظهر مع استخدام نجينلا ولكن تم الإبلاغ عنها مع العلاج بأدوية هرمون النمو الأخرى قد تتضمن ما يلي:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نمو الأنسجة (غير السرطانية أو السرطانية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري من النوع الثاني</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الضغط داخل القحف (الذي يتسبب في ظهور أعراض كالصداع الشديد أو اضطرابات في الرؤية أو القيء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدر أو وخز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل أو العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثدي عند الأولاد والرجال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي واحمرار وحكة في الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس الماء في الجسم (الذي يظهر في صورة انتفاخ الأصابع أو تورم الكاحلين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس (الذي يسبب أعراضًا تشمل ألم المعدة، أو الغثيان، أو القيء، أو الإسهال)</p><p><em>&nbsp;</em></p><p dir="RTL">وفي بعض الحالات النادرة للغاية، يمكن أن يسبب وجود ميتاكريزول التهابًا (تورمًا) في العضلات. ولهذا، إذا أصبت أنت أو الطفل الذي ترعاه بألم في العضلات أو في موضع الحقن، فأخبر الطبيب.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت أنت أو الطفل الذي ترعاه بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن ذلك أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:456px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">مركز الاتصال الموحد: ۱۹۹۹۹</p><p dir="RTL">&nbsp;البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى:</strong></p><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp; </em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصق القلم والعبوة الكرتونية بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">ينبغي عدم استخدام القلم مسبق التعبئة بعد مرور أكثر من ٢٨ يومًا بعد أول استخدام.</p><p>&nbsp;</p><p dir="RTL"><u>&nbsp;قبل أول استخدام </u><u>لنجينلا</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خزنه في البراد (الثلاجة) (بين درجتين مئويتين و٨ درجات مئوية). لاتقم بتجميده.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;احفظ نجينلا في العبوة الكرتونية الخارجية من أجل حمايته من الضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخرج نجينلا من البراد (الثلاجة) قبل الاستخدام. يمكن حفظ نجينلا في درجة حرارة الغرفة (حتى ٣٢ درجة مئوية) لمدة تصل إلى ٤ ساعات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء إذا لاحظت تعكر السائل أو تحول لونه إلى اللون الأصفر الداكن. لا تستخدم الدواء إذا كان يحتوي على رقائق أو جسيمات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ترج القلم. حيث يمكن أن يؤدي الرج إلى إتلاف الدواء.</p><p>&nbsp;</p><p dir="RTL"><u>بعد أول استخدام </u><u>لنجينلا</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم خلال ٢٨ يومًا بعد الاستخدام الأول. خزنه في البراد (الثلاجة) (بين درجتين مئويتين و٨ درجات مئوية). لا تقم بتجميده.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ نجينلا مع وضع غطاء القلم لحمايته من الضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;لا تُخزن القلم مسبق التعبئة مع وجود إبرة مثبتة به.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تخلص من القلم بعد تلقي آخر جرعة، حتى إذا كان يحتوي على كمية غير مستخدمة من الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن حفظ نجينلا في درجة حرارة الغرفة (حتى ٣٢ درجة مئوية) لمدة تصل إلى ٤ ساعات مع كل حقنة بحد أقصى ٥ مرات. عليك إعادة نجينلا إلى البراد (الثلاجة) مرة أخرى بعد كل استخدام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتركه في درجة حرارة الغرفة لأكثر من ٤ ساعات عند كل استخدام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تضع القلم في أي مكان تزيد فيه درجة الحرارة عن ٣٢ درجة مئوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا مر أكثر من ٢٨ يومًا بعد أول استخدام للقلم، فتخلص منه حتى إذا كان يحتوي على كمية غير مستخدمة من الدواء. إذا تعرض القلم الخاص بك أو بالطفل الذي ترعاه لدرجات حرارة أعلى من ٣٢ درجة مئوية، أو تُرك خارج البراد (الثلاجة) لأكثر من ٤ ساعات عند كل استخدام أو إذا وصل إجمالي مرات استخدامه إلى ٥ مرات، فتخلص منه حتى إذا كان يحتوي على كمية غير مستخدمة من الدواء.</p><p>&nbsp;</p><p dir="RTL">لمساعدتك على تذكر وقت التخلص من القلم، يمكنك كتابة تاريخ أول استخدام على ملصق القلم.</p><p>&nbsp;</p><p dir="RTL">قد تتبقى كمية صغيرة من الدواء في القلم بعد إعطاء جميع الجرعات بشكل صحيح. لا تحاول استخدام أي كمية متبقية من الدواء. بعد إعطاء آخر جرعة، يجب التخلص من القلم بشكل صحيح.</p><p>&nbsp;</p><p dir="RTL">&nbsp;لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمادة الفعالة هي سوماتروجون.</p><p>&nbsp;</p><p dir="RTL"><u>&nbsp;نجينلا ٢٤ ملجم سائل للحقن في قلم مسبق التعبئة</u></p><p dir="RTL">يحتوي مل واحد من السائل على ٢٠ ملجم من سوماتروجون.</p><p dir="RTL">&nbsp;يحتوي كل قلم مسبق التعبئة على ٢٤ ملجم من سوماتروجون في ١,٢ مل من السائل. يقوم كل قلم مسبق التعبئة بحقن جرعات تبدأ من ٠,٢ ملجم إلى ١٢ ملجم في كل حقنة فردية بزيادات قدرها ٠,٢ ملجم.</p><p>&nbsp;</p><p dir="RTL"><u>نجينلا ٦٠ ملجم سائل للحقن في قلم مسبق التعبئة</u></p><p dir="RTL">يحتوي مل واحد من السائل على ٥٠ ملجم من سوماتروجون.</p><p dir="RTL">يحتوي كل قلم مسبق التعبئة على ٦٠ ملجم من سوماتروجون في ١,٢ مل من السائل. يقوم كل قلم مسبق التعبئة بحقن جرعات تبدأ من ٠,٢ ملجم إلى ١٢ ملجم في كل حقنة فردية بزيادات قدرها ٠,٢ ملجم.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: ثلاثي سترات الصوديوم ثنائي الهيدرات، حمض الستريك أحادي الهيدرات، ل-هيستيدين، كلوريد الصوديوم (انظر القسم ٢ &quot;يحتوي نجينلا على الصوديوم&quot;) بولوكسامير ١٨٨، ميتا كريسول، ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">نجينلا عبارة عن سائل صافٍ عديم اللون أو يميل قليلًا إلى الأصفر الفاتح وهو مخصص للحقن ويأتي في قلم مسبق التعبئة.</p><p>&nbsp;</p><p dir="RTL">&nbsp;يتوفر نجينلا ٢٤ ملجم سائل للحقن في حجم عبوة تحتوي على قلم حقن واحد مسبق التعبئة. يكون غطاء القلم وزر الجرعات والملصق الموجود على القلم باللون الليلكي.</p><p>&nbsp;</p><p dir="RTL">يتوفر نجينلا ٦٠ ملجم سائل للحقن في حجم عبوة تحتوي على قلم حقن واحد مسبق التعبئة. يكون غطاء القلم وزر الجرعات والملصق الموجود على القلم باللون الأزرق.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك تصريح التسويق</strong></p><p dir="RTL">Pfizer Europe MA EEIG</p><p dir="RTL">Boulevard de la Plaine 17</p><p dir="RTL">1050 Bruxelles</p><p dir="RTL">Belgium، بلجيكا</p><p>&nbsp;</p><p dir="RTL"><strong>&rlm;الشركة الصانعة</strong><strong> </strong></p><p dir="RTL">فايزر مانفاكشرينج بيلجيم إن في</p><p dir="RTL">بورس، بلجيكا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ngenla 24 mg solution for injection in pre-filled pen
Ngenla 60 mg solution for injection in pre-filled pen

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ngenla 24 mg solution for injection in pre-filled pen

One mL of solution contains 20 mg of somatrogon*.
Each pre-filled pen contains 24 mg somatrogon in 1.2 mL solution.
Each pre-filled pen delivers doses from 0.2 mg to 12 mg in a single injection in 0.2 mg increments.

Ngenla 60 mg solution for injection in pre-filled pen

One mL of solution contains 50 mg of somatrogon. 
Each pre-filled pen contains 60 mg somatrogon in 1.2 mL solution.
Each pre-filled pen delivers doses from 0.5 mg to 30 mg in a single injection in 0.5 mg increments.

*Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells. 

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).

The solution is a clear and colourless to slightly light yellow solution with a pH of 6.6.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ngenla is indicated for the treatment of children and adolescents from 3&nbsp;years of age with growth disturbance due to insufficient secretion of growth hormone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated and monitored by physicians who are qualified and experienced in the diagnosis and management of paediatric patients with growth hormone deficiency (GHD).</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose is 0.66&nbsp;mg/kg body weight administered once weekly by subcutaneous injection.</p><p>&nbsp;</p><p>Each pre-filled pen is capable of setting and delivering the dose prescribed by the physician. Dose may be rounded up or down based on the physician&rsquo;s expert knowledge of the individual patient needs. When doses higher than 30&nbsp;mg are needed (i.e. bodyweight &gt;&nbsp;45&nbsp;kg), two injections have to be administered.</p><p>&nbsp;</p><p><em>Starting dose for patients switching from daily growth hormone medicinal products</em></p><p>For patients switching from daily growth hormone medicinal products, the weekly therapy with somatrogon may be initiated at a dose of 0.66&nbsp;mg/kg/week on the day following their last daily injection.</p><p>&nbsp;</p><p><em>Dose titration</em></p><p>Somatrogon dose may be adjusted as necessary, based on growth velocity, adverse reactions, body weight and serum insulin-like growth factor 1 (IGF-1) concentrations.</p><p>&nbsp;</p><p>When monitoring for IGF-1, samples should always be drawn 4&nbsp;days after the prior dose. Dose adjustments should be targeted to achieve average IGF-1 standard deviation score (SDS) levels in the normal range, i.e. between -2 and +2 (preferably close to 0&nbsp;SDS).</p><p>&nbsp;</p><p>In patients whose serum IGF-1 concentrations exceed the mean reference value for their age and sex by more than 2&nbsp;SDS, the dose of somatrogon should be reduced by 15%. More than one dose reduction may be required in some patients.</p><p>&nbsp;</p><p><em>Treatment evaluation and discontinuation</em></p><p>Evaluation of efficacy and safety should be considered at approximately 6 to 12&nbsp;month intervals and may be assessed by evaluating auxological parameters, biochemistry (IGF-1, hormones, glucose levels) and pubertal status. Routine monitoring of serum IGF-1 SDS levels throughout the course of treatment is recommended. More frequent evaluations should be considered during puberty.</p><p>&nbsp;</p><p>Treatment should be discontinued when there is evidence of closure of the epiphyseal growth plates (see section 4.3). Treatment should also be discontinued in patients having achieved final height or near final height, i.e. an annualised height velocity &lt;&nbsp;2&nbsp;cm/year or a bone age &gt;&nbsp;14&nbsp;years in girls or &gt;&nbsp;16&nbsp;years in boys.</p><p>&nbsp;</p><p><em>Missed dose</em></p><p>Patients should maintain their regular dosing day. If a dose is missed, somatrogon should be administered as soon as possible within 3&nbsp;days after the missed dose, and then the usual once weekly dosing schedule should be resumed. If more than 3&nbsp;days have passed, the missed dose should be skipped and the next dose should be administered on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.</p><p>&nbsp;</p><p><em>Changing the dosing day</em></p><p>The day of weekly administration can be changed if necessary as long as the time between two doses is at least 3&nbsp;days. After selecting a new dosing day, the once weekly dosing should be continued.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em><u>&nbsp;</u></em></p><p><em>Elderly </em></p><p>The safety and efficacy of somatrogon in patients over the age of 65&nbsp;years have not been established. No data are available.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Somatrogon has not been studied in patients with renal impairment. No dose recommendation can be made.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Somatrogon has not been studied in patients with hepatic impairment. No dose recommendation can be made.</p><p>&nbsp;</p><p><em>Paediatric population </em></p><p>The safety and efficacy of somatrogon in neonates, infants and children less than 3&nbsp;years of age have not yet been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>&nbsp;</p><p>Somatrogon is administered by subcutaneous injection.</p><p>&nbsp;</p><p>Somatrogon is to be injected in the abdomen, thighs, buttocks or upper arms. The site of injection should be rotated at each administration. Injections to the upper arms and buttocks should be given by the caregiver.</p><p>&nbsp;</p><p>The patient and caregiver should receive training to ensure understanding of the administration procedure to support self-administration.</p><p>&nbsp;</p><p>If more than one injection is required to deliver a complete dose, each injection should be administered at a different injection site.</p><p>&nbsp;</p><p>Somatrogon is to be administered once weekly, on the same day each week, at any time of the day.</p><p><u>&nbsp;</u></p><p><em>Ngenla</em><em> </em><em>24&nbsp;mg solution for injection in pre-filled pen</em></p><p>The pre-filled pen delivers doses from 0.2&nbsp;mg to 12&nbsp;mg of somatrogon in increments of 0.2&nbsp;mg (0.01&nbsp;mL).</p><p>&nbsp;</p><p><em>Ngenla</em><em> </em><em>60&nbsp;mg solution for injection in pre-filled pen</em></p><p>The pre-filled pen delivers doses from 0.5&nbsp;mg to 30&nbsp;mg of somatrogon in increments of 0.5&nbsp;mg (0.01&nbsp;mL).</p><p>&nbsp;</p><p>For instructions on the medicinal product before administration, see section 6.6 and at the end of the package leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to somatrogon (see section 4.4) or to any of the excipients listed in section 6.1.

Somatrogon must not be used when there is any evidence of activity of a tumour based on experience with daily growth hormone medicinal products. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting growth hormone (GH) therapy. Treatment should be discontinued if there is evidence of tumour growth (see section 4.4).

Somatrogon must not be used for growth promotion in children with closed epiphyses.

Patients with acute critical illness suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions must not be treated with somatrogon (regarding patients undergoing substitution therapy, see section 4.4).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability </u></p><p><u>&nbsp;</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><u>&nbsp;</u></p><p><u>Hypersensitivity</u></p><p>&nbsp;</p><p>Serious systemic hypersensitivity reactions (e.g. anaphylaxis, angioedema) have been reported with daily growth hormone medicinal products. If a serious hypersensitivity reaction occurs, use of somatrogon should be immediately discontinued; patients should be treated promptly per standard of care and monitored until signs and symptoms resolve (see section 4.3).</p><p><u>&nbsp;</u></p><p><u>Hypoadrenalism</u></p><p>&nbsp;</p><p>Based on published data patients receiving daily growth hormone therapy who have or are at risk for pituitary hormone deficiency(s) may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. In addition, patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of somatrogon treatment (see section 4.5). Patients should be monitored for reduced serum cortisol levels and/or need for glucocorticoid dose increases in those with known hypoadrenalism (see section 4.5).</p><p><u>&nbsp;</u></p><p><u>Thyroid function impairment</u></p><p>&nbsp;</p><p>Growth hormone increases the extrathyroidal conversion of T4 to T3 and may unmask incipient hypothyroidism. Patients with pre-existing hypothyroidism should be treated accordingly prior to the initiation of treatment with somatrogon as indicated based on clinical evaluation. As hypothyroidism interferes with the response to growth hormone therapy, patients should have their thyroid function tested regularly and should receive replacement therapy with thyroid hormone when indicated (see sections 4.5 and 4.8).</p><p><u>&nbsp;</u></p><p><u>Prader-Willi syndrome </u></p><p>&nbsp;</p><p>Somatrogon has not been studied in patients with Prader-Willi syndrome. Somatrogon is not indicated for the long-term treatment of paediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome unless they also have a diagnosis of GHD. There have been reports of sudden death after initiating therapy with growth hormone in paediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnoea, or unidentified respiratory infection.</p><p><u>&nbsp;</u></p><p><u>Glucose metabolism impairment</u></p><p>&nbsp;</p><p>Treatment with growth hormone medicinal products may reduce insulin sensitivity and induce hyperglycaemia. Additional monitoring should be considered in patients treated with somatrogon who have glucose intolerance, or additional risk factors for diabetes. In patients treated with somatrogon who have diabetes mellitus, hypoglycaemic medicinal products might require adjustment (see section 4.5).</p><p><u>&nbsp;</u></p><p><u>Neoplasm</u></p><p><u>&nbsp;</u></p><p>In patients with previous malignant disease, special attention should be given to signs and symptoms of relapse. Patients with pre-existing tumours or growth hormone deficiency secondary to an intracranial lesion should be examined routinely for progression or recurrence of the underlying disease process. In childhood cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropin after their first neoplasm. Intracranial tumours, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms.</p><p><u>&nbsp;</u></p><p><u>Benign intracranial hypertension</u></p><p>&nbsp;</p><p>Intracranial hypertension (IH) with papilledema, ataxia, visual changes, headache, nausea and/or vomiting has been reported in a small number of patients treated with growth hormone medicinal products. Funduscopic examination is recommended at the initiation of treatment and as clinically warranted. In patients with clinical or funduscopic evidence of IH, somatrogon should be temporarily discontinued. At present there is insufficient evidence to give specific advice on the continuation of growth hormone treatment in patients with resolved IH. If treatment with somatrogon is restarted, monitoring for signs and symptoms of IH is necessary.</p><p><u>&nbsp;</u></p><p><u>Acute critical illness</u></p><p><u>&nbsp;</u></p><p>In critically ill adult patients suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma or acute respiratory failure mortality was higher in patients treated with 5.3&nbsp;mg or 8&nbsp;mg somatropin daily (i.e. 37.1 &ndash; 56&nbsp;mg/week) compared to patients receiving placebo, 42% vs. 19%. Based on this information, these types of patients should not be treated with somatrogon. As there is no information available on the safety of growth hormone substitution therapy in acutely critically ill patients, the benefits of continued somatrogon treatment in this situation should be weighed against the potential risks involved. In all patients developing other or similar acute critical illness, the possible benefit of treatment with somatrogon must be weighed against the potential risk involved.</p><p><u>&nbsp;</u></p><p><u>Pancreatitis</u></p><p><u>&nbsp;</u></p><p>Although rare in patients treated with growth hormone medicinal products, pancreatitis should be considered in somatrogon-treated patients who develop severe abdominal pain during treatment.</p><p>&nbsp;</p><p><u>Scoliosis</u></p><p><u>&nbsp;</u></p><p>Because somatrogon increases growth rate, signs of development or progression of scoliosis should be monitored during treatment.</p><p>&nbsp;</p><p><u>Epiphyseal disorders </u></p><p>&nbsp;</p><p>Epiphyseal disorders, including slipped capital femoral epiphysis may occur more frequently in patients with endocrine disorders or in patients undergoing rapid growth. Any paediatric patient with the onset of a limp or complaints of hip or knee pain during treatment should be carefully evaluated.</p><p>&nbsp;</p><p><u>Oral oestrogen therapy </u></p><p>&nbsp;</p><p>Oral oestrogen influences the IGF-1 response to growth hormone. If a female patient taking somatrogon begins or discontinues oral oestrogen containing therapy, IGF-1 value should be monitored to determine if the dose of growth hormone should be adjusted to maintain the serum IGF‑1 levels within the normal range (see section 4.2). In female patients on oral oestrogen-containing therapy, a higher dose of somatrogon may be required to achieve the treatment goal (see section 4.5).</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p><em>Sodium content</em></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium free.&rsquo;</p><p><em>&nbsp;</em></p><p><em>Metacresol</em></p><p>Myositis is a very rare adverse event that may be related to the preservative metacresol. In the case of myalgia or disproportionate pain at injection site, myositis should be considered and if confirmed, other growth hormone medicinal products without metacresol should be used.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interactions studies in paediatrics have been performed.</p><p>&nbsp;</p><p><u>Glucocorticoids</u></p><p><u>&nbsp;</u></p><p>Concomitant treatment with glucocorticoids may inhibit the growth-promoting effects of somatrogon. Patients with adrenocorticotropic hormone (ACTH) deficiency should have their glucocorticoid replacement therapy carefully adjusted to avoid any inhibitory effect on growth. Therefore, patients treated with glucocorticoids should have their growth monitored carefully to assess the potential impact of glucocorticoid treatment on growth.</p><p><u>&nbsp;</u></p><p>Growth hormone decreases the conversion of cortisone to cortisol and may unmask previously undiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective (see section 4.4).</p><p>&nbsp;</p><p><u>Insulin and hypoglycaemic medicinal products</u></p><p>&nbsp;</p><p>In patients with diabetes mellitus requiring medicinal product therapy, the dose of insulin and/or oral/injectable hypoglycaemic medicinal products may require adjustment when somatrogon therapy is initiated (see section 4.4).</p><p>&nbsp;</p><p><u>Thyroid medicinal products </u></p><p><u>&nbsp;</u></p><p>Treatment with daily growth hormone may unmask previously undiagnosed or subclinical central hypothyroidism. Thyroxine replacement therapy may need to be initiated or adjusted (see section 4.4).</p><p>&nbsp;</p><p><u>Oral oestrogen therapy</u></p><p>&nbsp;</p><p>In female patients on oral oestrogen-containing therapy, a higher dose of somatrogon may be required to achieve the treatment goal (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Cytochrome P450 metabolised products</u></p><p>&nbsp;</p><p>Drug-drug interaction studies have not been performed with somatrogon. Somatrogon has been shown to induce CYP3A4 mRNA expression <em>in vitro</em>. The clinical significance of this is unknown. Studies with other human growth hormone (hGH) receptor agonists performed in growth hormone deficient children and adults, and healthy elderly men, suggest that administration may increase the clearance of compounds known to be metabolised by cytochrome P450 isoenzymes, especially CYP3A. The clearance of compounds metabolised by CYP3A4 (e.g. sex steroids, corticosteroids, anticonvulsants and ciclosporin) may be increased and could result in lower exposure of these compounds.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no data from the use of somatrogon in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). Ngenla is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether somatrogon/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from somatrogon therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>The risk of infertility in females or males of reproductive potential has not been studied in humans. In a rat study, the fertility in males and females was not affected (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ngenla has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>The commonly reported adverse reactions after treatment with somatrogon are injection site reactions (ISRs) (25.1%), headache (10.7% ) and pyrexia (10.2%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Safety data are derived from the phase 2, multi-centre safety and dose-finding study, and the pivotal phase 3, multi-centre non-inferiority study in paediatric patients with GHD (see section 5.1). The data reflect exposure of 265&nbsp;patients to somatrogon administered once weekly (0.66&nbsp;mg/kg/week).</p><p>&nbsp;</p><p>Table 1 presents the adverse reactions for somatrogon within the system organ class (SOC). The adverse reactions listed in the table below are presented by SOC and frequency categories, defined using the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000) or frequency not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1. Adverse reactions </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:108%"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known </strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaemia</p><p>Eosinophilia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypothyroidism</p></td><td style="vertical-align:top"><p>Adrenal insufficiency</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&nbsp;Allergic conjuctivitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash generalised</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Arthralgia</p><p>Pain in extremity</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Injection site reactions<sup>a</sup></p><p>Pyrexia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="7" style="vertical-align:top"><p><!--[if supportFields]><span
  style='mso-bookmark:TblFnTxtBkmkID_20611152946'></span><span
  style='mso-element:field-begin'></span><span style='mso-bookmark:TblFnTxtBkmkID_20611152946'><span
  style='font-size:9.0pt;mso-ansi-language:EN-US'><span
  style='mso-spacerun:yes'> </span>SEQ TblFnSeqID_20611152946 \n \* alphabetic
  \* MERGEFORMAT </span></span><span style='mso-bookmark:TblFnTxtBkmkID_20611152946'><span
  style='font-size:10.0pt;mso-ansi-language:EN-US'><span style='mso-element:
  field-separator'></span></span></span><![endif]-->a<!--[if supportFields]><span
  style='mso-bookmark:TblFnTxtBkmkID_20611152946'></span><span
  style='mso-element:field-end'></span><![endif]--> Injection site reactions include the following: injection site pain, erythema, pruritus, swelling, induration, bruising, haemorrhage, warmth, hypertrophy, inflammation, deformation, urticaria.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p>Injection site reaction</p><p>In the phase 3 clinical study, reporting of ISRs was actively solicited during the course of the study. In the majority of cases, local ISRs tended to be transient, occurred mainly in the first 6 months of treatment and were mild in severity; ISRs had a mean onset on the day of the injection and a mean duration of &lt;&nbsp;1&nbsp;day. Among them, injection site pain, erythema, pruritus, swelling, induration, bruising, hypertrophy, inflammation and warmth were reported in 43.1% of patients treated with somatrogon compared to 25.2% of patients administered daily injections of somatropin.</p><p>&nbsp;</p><p>In the long-term OLE of the clinical phase 3 study, local ISRs were similar in nature and severity, and reported early in subjects switching from somatropin to somatrogon treatment. ISRs were reported in 18.3% of patients originally treated with somatrogon in the main study and continuing treatment in the OLE portion of the study, and likewise, 37% were reported among patients originally treated with somatropin that were switched in the OLE portion of the study to treatment with somatrogon.</p><p>&nbsp;</p><p>Immunogenicity</p><p>In the pivotal safety and efficacy study, among 109&nbsp;subjects treated with somatrogon, 84&nbsp;(77.1%) tested positive for anti-drug antibodies (ADAs). There were no clinical or safety effects observed with the formation of antibodies.</p><p>&nbsp;</p><p><em>Other adverse drug reactions for somatropin may be considered class effects, such as</em><em>:</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neoplasms benign and malignant: (see section 4.4).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metabolism and nutrition disorders: diabetes mellitus type 2 (see section 4.4).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nervous system disorders: benign intracranial hypertension (see section 4.4), paraesthesia.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Musculoskeletal, connective tissue, and bone disorders: myalgia.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reproductive system and breast disorders: gynaecomastia.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and subcutaneous tissue disorders: skin rash, urticaria and pruritus.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General disorders and administration site conditions: peripheral oedema, facial oedema.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal disorders: pancreatitis (see section 4.4).</p><p>&nbsp;</p><p><em>Metacresol</em></p><p>This medicinal product contains metacresol which may contribute to painful injections (see section 4.4).</p><p><s>&nbsp;</s></p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Center (NPC).</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:456px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses of somatrogon higher than 0.66&nbsp;mg/kg/week have not been studied.</p><p>&nbsp;</p><p>Based on experience with daily growth hormone medicinal products, short-term overdose could lead initially to hypoglycaemia and subsequently to hyperglycaemia. Long-term overdose could result in signs and symptoms of gigantism and/or acromegaly consistent with the effects of growth hormone excess.</p><p>&nbsp;</p><p>Treatment of overdose with somatrogon should consist of general supportive measures.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Pituitary and hypothalamic hormones and analogues, somatropin and somatropin agonists, ATC code: H01AC08.</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Somatrogon is a glycoprotein comprised of the amino acid sequence of hGH with one copy of the of C-terminal peptide (CTP) from the beta chain of human chorionic gonadotropin (hCG) at the N-terminus and two copies of CTP (in tandem) at the C-terminus. The glycosylation and CTP domains account for the half-life of somatrogon, which allows for weekly dosing.</p><p>&nbsp;</p><p>Somatrogon binds to the GH receptor and initiates a signal transduction cascade culminating in changes in growth and metabolism. Consistent with GH signalling, somatrogon binding leads to activation of the STAT5b signalling pathway and increases the serum concentration of IGF-1. IGF-1 was found to increase in a dose-dependent manner during treatment with somatrogon partially mediating the clinical effect. As a result, GH and IGF-1 stimulate metabolic changes, linear growth and enhance growth velocity in paediatric patients with GHD.</p><p><s>&nbsp;</s></p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>In clinical studies, somatrogon increases IGF-1. Pharmacodynamic evaluations performed approximately 96&nbsp;hours after dose administration in order to assess the mean IGF-1 standard deviation score (SDS) over the dosing interval showed IGF-1 values normalised in treated subjects at one month of treatment.</p><p><s>&nbsp;</s></p><p><em>Water and mineral metabolism</em></p><p>Somatrogon induces the retention of phosphorus.</p><p><s>&nbsp;</s></p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The safety and efficacy of somatrogon for the treatment of children and adolescents from 3&nbsp;years of age with GHD were evaluated in two multi-centre randomised, open-label controlled clinical studies. Both studies included a 12‑month main study period that compared once weekly somatrogon to somatropin administered once daily followed by a single arm OLE period during which all patients were administered somatrogon once weekly. The primary efficacy endpoint for both studies was annualised height velocity (HV) following 12&nbsp;months of treatment. Other endpoints reflective of catch-up growth such as change in height SDS from baseline and height SDS were also evaluated in both studies.</p><p>&nbsp;</p><p>The pivotal phase 3 multi-centre non-inferiority study evaluated the safety and efficacy of 0.66&nbsp;mg/kg/week dose of somatrogon compared to 0.034&nbsp;mg/kg/day of somatropin in 224&nbsp;pre-pubertal paediatric patients with GHD. The mean age across the treatment groups was 7.7&nbsp;years (min 3.01, max&nbsp;11.96), 40.2% of patients were &gt;&nbsp;3&nbsp;years to &le;&nbsp;7&nbsp;years, 59.8% were &gt;&nbsp;7&nbsp;years. 71.9% of patients were male and 28.1% were female. In this study, 74.6% of patients were White, 20.1% were Asian; 0.9% were Black. Baseline disease characteristics were balanced across both treatment groups. Approximately 68% of patients had peak plasma GH levels of &le;&nbsp;7&nbsp;ng/mL, and the mean height was below -2&nbsp;SDS.</p><p>&nbsp;</p><p>Once weekly somatrogon was non-inferior based on HV at 12&nbsp;months compared to somatropin administered once daily (see Table 2). Once weekly somatrogon also produced an increase in IGF‑1 SDS values, from a mean of -1.95 at baseline to a mean of 0.65 at 12&nbsp;months.</p><p>&nbsp;</p><p><strong>Table 2. Efficacy of somatrogon compared to somatropin in paediatric patients with GHD at month&nbsp;12 </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:608px"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Treatment parameter</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Treatment group</strong></p><p>&nbsp;</p></td><td rowspan="3"><p><strong>&nbsp;</strong></p><p><strong>LSM difference</strong></p><p><strong>(95% CI)</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td><p><strong>Somatrogon (N=109)</strong></p></td><td><p><strong>Somatropin (N=115)</strong></p></td></tr><tr><td><p><strong>LSM estimate</strong></p></td><td><p><strong>LSM estimate</strong></p></td></tr><tr><td style="vertical-align:top"><p>Height velocity (cm/yr)</p></td><td style="vertical-align:top"><p>10.10</p></td><td style="vertical-align:top"><p>9.78</p></td><td style="vertical-align:top"><p>0.33 (-0.24, 0.89)</p></td></tr><tr><td style="vertical-align:top"><p>Height standard deviation score</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>-1.94</p></td><td style="vertical-align:top"><p>-1.99</p></td><td style="vertical-align:top"><p>0.05 (-0.06, 0.16)</p></td></tr><tr><td style="vertical-align:top"><p>Change in height standard deviation score from baseline</p></td><td style="vertical-align:top"><p>0.92</p></td><td style="vertical-align:top"><p>0.87</p></td><td style="vertical-align:top"><p>0.05 (-0.06, 0.16)</p></td></tr></tbody></table><p>Abbreviations: CI=confidence interval; GHD=growth hormone deficiency; LSM=least square mean; N=number of patients randomised and treated.</p><p><u>&nbsp;</u></p><p>In the open-label extension of the pivotal phase 3 study, 91&nbsp;patients received 0.66&nbsp;mg/kg/week of somatrogon for at least 2&nbsp;years and provided height data. A progressive gain in height SDS from baseline was observed at 2&nbsp;years [cumulative change in height SDS mean (SD)&nbsp;=&nbsp;1.38 (0.78), median&nbsp;=&nbsp;1.19 (range: 0.2, 4.9)].</p><p><u>&nbsp;</u></p><p>In the phase 2, multi-centre safety and dose-finding study, 31&nbsp;patients received up to 0.66&nbsp;mg/kg/week of somatrogon for up to 7.7&nbsp;years. At the last assessment, height SDS [mean (SD)] was -0.39&nbsp;(0.95) and cumulative change in height SDS [mean (SD)] from baseline was 3.37&nbsp;(1.27).</p><p>&nbsp;</p><p><em>Treatment burden </em></p><p>In a phase 3 randomised, open-label, crossover study in 87&nbsp;paediatric patients with GHD, the impact of somatrogon administered once weekly (0.66&nbsp;mg/kg/week) on treatment burden was compared to daily somatropin. Somatrogon administered once weekly demonstrated significant improvement (reduction) in treatment burden for the patient, improved (reduced) treatment burden for the caregiver, greater patient convenience, greater intent to comply and greater patient preference.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Ngenla in all subsets of the paediatric population for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Somatrogon pharmacokinetics (PK) was assessed using a population PK approach for somatrogon in 42&nbsp;paediatric patients (age range 3-15.5&nbsp;years) with GHD.</p><p><strong>&nbsp;</strong></p><p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>Following subcutaneous injection, serum concentrations increased slowly, peaking 6 to 18&nbsp;hours after dosing.</p><p>&nbsp;</p><p>In paediatric patients with GHD, somatrogon exposure increases in a dose-proportional manner for doses of 0.25&nbsp;mg/kg/week, 0.48&nbsp;mg/kg/week and 0.66&nbsp;mg/kg/week. There is no accumulation of somatrogon after once weekly administration. In paediatric patients with GHD, the population PK estimated steady-state peak concentrations following 0.66&nbsp;mg/kg/week was 636&nbsp;ng/mL. Patients who tested positive for ADA had an approximately 45% higher steady-state average concentration.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>In paediatric patients with GHD, the population PK estimated apparent central volume of distribution was 0.728&nbsp;L/kg and apparent peripheral volume of distribution was 0.165&nbsp;L/kg.<u> </u></p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>The metabolic fate of somatrogon is believed to be classical protein catabolism, with subsequent reclamation of the amino acids and return to the systemic circulation.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>&nbsp;</p><p>In paediatric patients with GHD, the population PK estimated apparent clearance was 0.0317&nbsp;L/h/kg. Patients who tested positive for ADA had an approximately 25.8% decrease in apparent clearance. With a population PK estimated effective half-life of 28.2&nbsp;hours, somatrogon will be present in the circulation for about 6&nbsp;days after the last dose.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p><strong>&nbsp;</strong></p><p><em>Age, race, gender, body weight</em></p><p>Based on population PK analyses, age, sex, race and ethnicity do not have a clinically meaningful effect on the pharmacokinetics of somatrogon in paediatric patients with GHD. The exposure of somatrogon decreases with an increase in body weight. However, the somatrogon dose of 0.66&nbsp;mg/kg/week provides adequate systemic exposure to safely achieve efficacy over the weight range evaluated in the clinical studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and repeat-dose toxicity.</p><p>&nbsp;</p><p>Reproductive and developmental toxicity studies were conducted in rats with somatrogon administered subcutaneously at doses up to 30&nbsp;mg/kg (associated with exposures levels approximately 14&nbsp;times the maximum recommended human dose based on AUC).</p><p>&nbsp;</p><p>Somatrogon induced an increase in oestrous cycle length, copulatory interval, and number of corpora lutea in female rats but no effects on mating indices, fertility or early embryonic development.</p><p>&nbsp;</p><p>No effects of somatrogon were observed on embryo-foetal development.</p><p>&nbsp;</p><p>In a pre-postnatal development study somatrogon elicited an increase in first generation (F1) mean body weights (both sexes) as well as an increase in the mean copulatory interval in F1 females at the highest dose (30&nbsp;mg/kg), which was consistent with a longer oestrous cycle length; however, there were no associated effects on mating indices.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trisodium citrate dihydrate</p><p>Citric acid monohydrate</p><p>L-Histidine</p><p>Sodium chloride</p><p>m-Cresol</p><p>Poloxamer 188</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Before first use

3 years. 
Store in refregriator 2 °C to 8 °C. 
Do not freeze.

Prior to the first use store Ngenla in a refrigerator. The unopened pre-filled pen may temporarily be held for up to 4 hours at temperatures up to 32 °C. 

After first use

28 days. 
Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Keep Ngenla with the pen cap attached in order to protect from light.

Ngenla may be held at room temperature (up to 32 °C) for up to 4 hours with each injection for a maximum of 5 times. Return Ngenla to the refrigerator again after each use. Do not expose Ngenla to temperatures above 32 °C or leave at room temperature for more than 4 hours with each use. The Ngenla pen should be discarded if it has been used 5 times, if it has been exposed to temperatures higher than 32 °C or if it has been removed from the refrigerator for more than 4 hours with each use.

Chemical and physical in-use stability has been demonstrated for 28 days from the date of first use of the pre-filled pen, when the pre-filled pen has been stored at 2 °C to 8 °C in between each use. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C to 8&nbsp;&deg;C). Do not freeze. Keep Ngenla in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after first use of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Ngenla 24&nbsp;mg solution for injection in pre-filled pen</u></p><p>&nbsp;</p><p>This multi-dose disposable pre-filled pen, which consists of a cartridge (Type&nbsp;I clear glass) permanently sealed in a plastic pen, contains 1.2&nbsp;mL of somatrogon. The cartridge is closed at the bottom with a rubber stopper (Type&nbsp;I rubber closures) shaped as a plunger and at the top with a rubber stopper (Type&nbsp;I rubber closures) shaped as a disc and sealed with an aluminium cap. The pen cap, dose button and label on the pen are coloured lilac.</p><p>&nbsp;</p><p>Pack size of 1&nbsp;pre-filled pen.</p><p>&nbsp;</p><p><u>Ngenla 60&nbsp;mg solution for injection in pre-filled pen</u></p><p>&nbsp;</p><p>This multi-dose disposable pre-filled pen, which consists of a cartridge (Type&nbsp;I clear glass) permanently sealed in a plastic pen, contains 1.2&nbsp;mL of somatrogon. The cartridge is closed at the bottom with a rubber stopper (Type I&nbsp;rubber closures) shaped as a plunger and at the top with a rubber stopper (Type&nbsp;I rubber closures) shaped as a disc and sealed with an aluminium cap. The pen cap, dose button and label on the pen are coloured blue.</p><p>&nbsp;</p><p>Pack size of 1&nbsp;pre-filled pen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solution should appear clear and colourless to slightly light yellow solution and be free of particles. Do not inject the medicinal product if it is cloudy, dark yellow, or contains particulate matter. Do not shake, shaking can damage the medicinal product.</p><p>&nbsp;</p><p>Each Ngenla pre-filled pen is for use by a single patient. A Ngenla pre-filled pen must never be shared between patients, even if the needle is changed.</p><p>&nbsp;</p><p>The pre-filled pen should only be used up to 28&nbsp;days after first use and before the expiry date.</p><p>&nbsp;</p><p>Do not freeze the medicinal product. Do not expose to heat (above 32&nbsp;&deg;C). Do not use Ngenla if it has been frozen or exposed to heat, discard.</p><p>&nbsp;</p><p><u>Dose preparation </u></p><p><u>&nbsp;</u></p><p>The pen may be used straight from the refrigerator. For a more comfortable injection, the pre-filled pen containing the sterile solution of somatrogon may be allowed to reach room temperature up to 32&nbsp;&deg;C for up to 30&nbsp;minutes. The solution in the pen should be inspected for flakes, particles and colouration. The pen should not be shaken. If flakes, particles or discolouration are observed, the pen should not be used.</p><p>&nbsp;</p><p><u>Administration </u></p><p><u>&nbsp;</u></p><p>The designated injection site should be prepared as instructed in the Instructions for Use. It is recommended to rotate the injection site at each administration. When in use, always replace the pen cap on the pre-filled pen after each injection. Return Ngenla to the refrigerator again after each use. A new needle must always be attached before use. Needles must not be re-used. The injection needle should be removed after each injection and the pen should be stored without a needle attached. This may prevent blocked needles, contamination, infection, leakage of solution and inaccurate dosing.</p><p>&nbsp;</p><p>In the event of blocked needles (i.e. liquid does not appear at the needle tip), patients must follow the instructions described in the Instructions for Use accompanying the package leaflet.</p><p>&nbsp;</p><p>Sterile needles are required for administration but are not included. Ngenla can be administered with a needle from 4&nbsp;mm to 8&nbsp;mm and between 30G and32G.</p><p>&nbsp;</p><p>Instructions for the preparation and administration of the product are given in the package leaflet and Instructions For Use.</p><p>&nbsp;</p><p><u>Disposal </u></p><p><u>&nbsp;</u></p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements. If the pre-filled pen is empty, has been exposed to temperatures higher than 32&nbsp;&deg;C, has been removed from the refrigerator for more than 4&nbsp;hours with each use, has been used 5&nbsp;times, or it has been more than 28&nbsp;days after first use, it should be disposed of even if it contains unused medicinal product. A small amount of the sterile somatrogon solution may remain in the pen after all doses have been correctly given. Patients should be instructed not to use the remaining solution, but to properly discard the pen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Manufactured by
Pfizer Manufacturing Belgium NV
Puurs, Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>